STAT+: Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it’s time to show results. 
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks